Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01854268
Other study ID # 32-2013
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2013
Est. completion date May 2014

Study information

Verified date February 2022
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cough is a defensive behavior that involves three stages. A large inspiratory phase, a compression phase where the vocal folds close and subglottal pressure is developed, and an expiratory phase. Cough serves to protect the upper and lower airways from material such as liquids, solids, or saliva, that have been aspirated. There are two types of cough: voluntary and reflex cough. Voluntary cough involves a cough to command. Reflex cough is a cough that is generated secondary to a stimulus in or near the airway. There has been some research regarding the differences between voluntary and reflex cough. However, no research has described the differences in airflow or movement pattern (kinematics) between the two types of cough. This study seeks to determine the respiratory kinematics and airflow differences between voluntary and reflex cough in healthy participants.


Description:

As a participant, completion of this study will require the following: Investigators will first place cotton elastic bands around your chest and abdomen so that measures of chest wall and abdominal movements can be measured. Then, tests of your breathing made from pulmonary function testing will be completed. Investigators will then have you complete a maximum inspiration followed by a maximum expiration three times. Investigators will ask you to produce a voluntary cough three times into a facemask which is attached to a computer. Then the investigators will provide you with nebulized water (FOG) through the facemask for up to a minute three times. You will have a minute break in between each presentation. Finally, the investigators will provide you with a nebulized dose of Capsaicin, which is derived from hot peppers, through the same facemask used in all of the above tasks. You will receive three doses of capsaicin and be provided with water at any time during the study.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date May 2014
Est. primary completion date May 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Healthy adults between the ages of 18-80 years. - Ability to provide informed consent. Exclusion Criteria: - No history of smoking within the last 5 years as this reduces the sensitivity to capsaicin - No history of neurological disease (i.e. Parkinson's disease, stroke, traumatic brain injury, etc.) - No known allergy to capsaicin - No history of respiratory disease (i.e. asthma, chronic obstructive pulmonary disease, or respiratory infection within the last 5 weeks.)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Healthy adults who receive capsaicin
Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.

Locations

Country Name City State
United States University of Florida, Dauer Hall Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lung Volume Initiation Respiratory kinematic measure: lung volume initiation (LVI) Lung volume initiation is a measure of the volume of air in the lungs prior to a respiratory task. 1 hour
Secondary Peak Expiratory Airflow Rate Airflow measures: Peak expiratory airflow rate Peak expiratory flow rate is a measure of the velocity of air expelled from the respiratory apparatus during cough. Measured in liters/second. 1 hour
Secondary Urge-to-cough Urge-to-cough: A measure of respiratory sensation that rates the perceived magnitude of the need to cough on a Borg scale (0=no urge-to-cough; 10=maximal urge-to-cough). 1 hour
See also
  Status Clinical Trial Phase
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Not yet recruiting NCT04064333 - Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care N/A
Recruiting NCT02482818 - Efficacy of Pregabalin on Chronic Cough Phase 1/Phase 2
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Active, not recruiting NCT02065440 - The Effect of Ebastine/Pseudoephedrine on Subacute Cough N/A
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Completed NCT00353951 - An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care N/A
Terminated NCT00668317 - Bronchial Hyper-responsiveness in Reflux Cough Phase 3
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Recruiting NCT05115097 - AI Evaluation of COVID-19 Sounds (AI-EChOS)
Recruiting NCT04457011 - Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children Phase 2
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT03922373 - A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects Phase 1
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT05570539 - Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation Phase 1
Completed NCT03999203 - A Cross-sectional Study to Measure Cough in Severe Asthma N/A
Active, not recruiting NCT05479929 - Work of Breathing Assessment in Triage Scale
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A